The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 03, 2021
Filed:
Sep. 25, 2019
Applicant:
Gemvax & Kael Co., Ltd., Daejeon, KR;
Inventor:
Sang Jae Kim, Seoul, KR;
Assignee:
GemVax & KAEL Co., Ltd., Daejeon, KR;
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/02 (2006.01); A61K 38/10 (2006.01); A61K 38/17 (2006.01); A61K 38/45 (2006.01); A61P 17/06 (2006.01); A61P 27/02 (2006.01); A61P 27/06 (2006.01); A61P 3/10 (2006.01); A61P 43/00 (2006.01); A61P 9/10 (2006.01); C07K 1/10 (2006.01); C07K 1/16 (2006.01); C07K 7/08 (2006.01); C07K 1/04 (2006.01); C07K 1/06 (2006.01);
U.S. Cl.
CPC ...
A61K 38/02 (2013.01); A61K 38/10 (2013.01); A61K 38/17 (2013.01); C07K 1/045 (2013.01); C07K 1/061 (2013.01); C07K 1/10 (2013.01); C07K 1/16 (2013.01);
Abstract
A pharmaceutical composition for preventing or treating ophthalmopathy is described. More particularly, a composition comprising a peptide derived from telomerase and being effective in treating and preventing ophthalmopathy is described. The peptide derived from telomerase, a peptide having a sequence 80% identical to the sequence thereof, or a peptide as a fragment thereof is superiorly effective in treating ophthalmopathy.